C12N 2770/24362
By genetic engineering
Official title: by genetic engineering
C12N2770/24362 (By genetic engineering) appears on 14 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 18
- Assignees
- 9
- Inventors
- 25
- Latest grant
- 12 Jun 2018
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 2 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 2 |
| 2011 | 2 | 2 |
| 2012 | 1 | 2 |
| 2013 | 1 | 1 |
| 2014 | 2 | 0 |
| 2015 | 1 | 1 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 2 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
By publication year.
Recent patents
- Recombinant classical swine fever virus (CSFV) comprising substitution in the TAV epitope of the E2 protein12 Jun 2018US 9,993,544 B2Boehringer Ingelheim Vetmedica GmbH
- BVDV vaccine30 Jan 2018US 9,878,030 B2Intervet Inc.
- Live attenuated antigenically marked classical swine fever vaccine31 May 2016US 9,352,032 B2The United States of America as represented by the Secretary of Agriculture
- N-linked glycosylation alteration in E0 and E2 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine24 Feb 2015US 8,961,996 B2The United States of America as represented by the Secretary of Agriculture
- Attenuated pestivirus25 Nov 2014US 8,895,026 B2Boehringer Ingelheim Vetmedica GmbH
- Recombinant classical swine fever virus e2 protein24 Oct 2024US 2024/0350610 A1Boehringer Ingelheim Vetmedica (China) Co., Ltd.
- Recombinant classical swine fever virus15 Jun 2023US 2023/0181710 A1
- Pestivirus marker vaccine8 Aug 2019US 2019/0240311 A1Intervet Inc.
- Recombinant classical swine fever virus (csfv) comprising substitution in the tav epitope of the e2 protein4 May 2017US 2017/0119870 A1Boehringer Ingelheim Vetmedica GmbH
- Live Attenuated Antigenically Marked Classical Swine Fever Vaccine10 Sep 2015US 2015/0250866 A1The United States of America as represented by the Secretary of Agriculture
Most cited
By later US patents
- Safe attenuated bovine viral diarrhea viruses for use in pregnant cows9US 6,610,305 B1Boehringer Ingelheim Vetmedica GmbH · 2003
- N-linked glycosylation alteration in E1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine6US 8,114,852 B2The United States of America as represented by the Secretary of Agriculture · 2012
- N-linked glycosylation alteration in E1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine5US 8,426,575 B2The United States of America as represented by the Secretary of Agriculture · 2013
- Infectious bovine viral diarrhea virus clone4US 7,135,561 B2Boehringer Ingelheim Vetmedica GmbH · 2006
- Replicons of pestviruses that do not express C and or E1 protein and infectious viral particles containing same, that can be used in vaccines2US 7,244,434 B2Intervet International B.V. · 2007